Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ANDA 180-Day "Triggering Period" Favored By FTC, Opposed By Industry

Nov 22 1999

• By The Tan Sheet

Related Content

Generic exclusivity "successful defense" removal is anticompetitive -- NAPM.

Jun 29 1998

180-Day Exclusivity Must Begin Within 180-Day "Triggering Period" - FDA

Aug 09 1999

Novopharm Entitled To OTC Ranitidine Generic Exclusivity - Federal Judge

Jun 21 1999

Additional Topics

OTC Drugs Consumer

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window